ReviewPediatric nephrology (Berlin, Germany)2005
Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions.
Review in Pediatric nephrology (Berlin, Germany), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 70 citations in OpenAlex.
- Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome.Journal of the American Society of Nephrology : JASN · 2013Trial
- Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2010Trial
- Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.British journal of clinical pharmacology · 2010Trial
- Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2010Trial
- Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2007Trial
- A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2007Trial
- Article
- Article
- The Application of Inosine 5'-Monophosphate Dehydrogenase Activity Determination in Peripheral Blood Mononuclear Cells for Monitoring Mycophenolate Mofetil Therapy in Children with Nephrotic Syndrome.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Cyclophosphamide versus cyclosporine A therapy in steroid-resistant nephrotic syndrome: a retrospective study with a mean 5-year follow-up.The Journal of international medical research · 2018Article
- Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment.Pediatric nephrology (Berlin, Germany) · 2017Article
- [Comparison of therapeutic effects of prednisone combined with mycophenolate mofetil versus cyclosporin A in children with steroid-resistant nephrotic syndrome].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2016Article
- Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children.Pediatric nephrology (Berlin, Germany) · 2015Observational
- Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor.World journal of nephrology · 2013Review
- A distinct lymphocyte distribution in relapse after rituximab for steroid-dependent nephrotic syndrome.CEN case reports · 2013Article
- Nephrotic syndrome.Indian journal of pediatrics · 2012Review
- Childhood nephrotic syndrome--current and future therapies.Nature reviews. Nephrology · 2012Review
- Mycophenolate mofetil monotherapy in the management of paediatric uveitis.Eye (London, England) · 2011Article
- Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome.Clinical journal of the American Society of Nephrology : CJASN · 2010Article
- Corticosteroids vs. corticosteroids plus cycloporin A in adult minimal changes disease.BMC research notes · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinicians are often faced with therapeutic dilemmas and challenges while treating children with frequently relapsing steroid-dependent nephrotic syndrome (SDNS) and steroid-resistant nephrotic syndrome (SRNS). In the past, children with SDNS have been treated with long-term alternate day steroids cyclophosphamide, cyclosporine (CSA), chlorambucil, levamisole, and azathioprine. The essential aim of these therapies is to maintain remission while limiting exposure to steroids. These medications have variable efficacy and undesirable toxicity profiles. Recently, mycophenolate mofetil (MMF) has emerged as a new therapeutic option for the management of SDNS in a few uncontrolled clinical trials. Preliminary data are encouraging. MMF was found to be useful in maintaining remission and has a steroid-sparing effect. Clearly, more data are needed to further characterize the safety and efficacy of MMF, define adequate length of treatment, and optimize drug exposure and monitoring. The management of SRNS is primarily aimed at decreasing proteinuria and inducing remission, if possible. By doing so, one would aim to preserve renal function. CSA therapy is known to be useful in this regard but has undesirable side effects, the most concerning being nephrotoxicity. MMF in combination with steroids and angiotensin-converting enzyme-inhibitor drugs is known to have some efficacy in the management of SRNS. These preliminary data have prompted the National Institutes of Health to sponsor a multicentric controlled trial to compare the safety and efficacy of MMF with that of CSA in the treatment of steroid-resistant focal segmental glomerulosclerosis (FSGS). If MMF therapy is found to be efficacious, it would help obviate the need for CSA and its associated nephrotoxicity. Clearly, MMF has emerged as an important new therapeutic option for the treatment of childhood nephrotic syndrome and FSGS. Further data are required to assess those conditions most likely to respond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.